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OBJECTIVES We sought to determine trends in the treatment of myocardial infarction from 1990 through
1999 in the U.S. and to relate these trends to current guidelines.
BACKGROUND Limited data are available to show how recent clinical trials and clinical guidelines have
impacted treatment of myocardial infarction.
METHODS Temporal trends in myocardial infarction treatment and outcome were assessed by using data
from 1,514,292 patients in the National Registry of Myocardial Infarction (NRMI) 1, 2 and
3 from 1990 through 1999.
RESULTS During this interval, the use of intravenous thrombolytic therapy declined from 34.3% to
20.8%, but the use of primary angioplasty increased from 2.4% to 7.3% (both p 5 0.0001).
The median “door-to-drug” time among thrombolytic therapy recipients fell from 61.8 to
37.8 min (p 5 0.0001), primarily owing to shorter “door-to-data” and “data-to-decision”
times. The prevalence of non–Q wave infarctions increased from 45% in 1994 to 63% in 1999
(p 5 0.0001). From 1994 through 1999, there was increased usage of beta-blockers, aspirin
and angiotensin-converting inhibitors, both during the first 24 h after admission and on
hospital discharge (all p 5 0.0001). Between 1990 and 1999, the median duration of hospital
stay fell from 8.3 to 4.3 days, and hospital mortality declined from 11.2% to 9.4% (both p 5
0.0001).
CONCLUSIONS The NRMI data from 1990 through 1999 demonstrate that the recommendations of recent
clinical trials and published guidelines are being implemented, resulting in more rapid
administration of intravenous thrombolytic therapy, increasing use of primary angioplasty and
more frequent use of adjunctive therapies known to reduce mortality, and may be contributing
to the higher prevalence of non–Q wave infarctions, shorter hospital stays and lower hospital
mortality. (J Am Coll Cardiol 2000;36:2056–63) © 2000 by the American College of
Cardiology
The treatment of acute myocardial infarction (AMI) in the
U.S. has undergone remarkable evolution over the decade of
the 1990s. This evolution has primarily been driven by
increasing awareness of therapies that have been shown by
controlled, clinical trials to improve outcome (1) and that
have subsequently been promoted by expert panels and
formal published guidelines (2). However, a secondary, but
powerful, motivation to change practice patterns has been
economic pressure stemming from health care reform.
In July 1990, the National Registry of Myocardial Infarc-
tion (NRMI) was initiated to provide participating hospitals
a means of tracking the characteristics, treatment and
outcome of their patients with AMI. The composite data
from the 1,514,292 patients entered from 1990 through
1999 in the first three phases of NRMI (NRMI 1, 2 and 3)
should provide insight into the evolving national practice
patterns for treatment of AMI. This report describes trends
in the presenting characteristics, treatment and outcome of
patients with AMI from 1990 through 1999, as reflected by
this large U.S. registry, and relates these trends to the
recommendations of recent clinical trials and to heath care
reform.
METHODS
Data collection. The NRMI is an industry-sponsored,
prospective, observational study (3). On entering NRMI,
hospitals were asked to complete a form characterizing their
facilities and services and then to record data from consec-
utive patients with AMI onto two-page case report forms,
which were forwarded to an independent statistical center.
Case report forms were less detailed for NRMI 1 (1990–
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1994) than for NRMI 2 (1994–1998) or NRMI 3 (1998 to
present). Hospitals received quarterly reports summarizing
local registry data, as well as parallel data from the state,
nation and hospitals of similar bed size and invasive cardio-
vascular capability. To ensure quality control of registry
data, registry coordinators were trained in data entry,
utilizing a standardized manual of instructions and defini-
tions. Case report forms were required to pass systematic
range and internal consistency checking. Hospitals obtained
approval of the registry data collection process as dictated by
local policy.
Trend analysis. Data were grouped according to the cal-
endar year of each patient’s hospital arrival. Phase 1 of
NRMI began in July 1990, so the initial period of data
collection was six months in duration. For data variables
common among NRMI 1, 2 and 3, trends over the period
1990–1999 were assessed. For variables contained only in
the more detailed NRMI 2 and 3 data bases, trend analyses
were confined to the period 1994–1999.
Definitions. Myocardial infarction was defined by local
hospital criteria, usually including a history suggestive of
AMI accompanied by either total creatine kinase or creatine
kinase, MB fraction greater than or equal to twice the upper
limit of normal for the hospital’s laboratory, or electrocar-
diographic (ECG) evidence of AMI, or, in the absence of
these, alternative enzymatic, scintigraphic, echocardio-
graphic or autopsy evidence of AMI—culminating in an
International Classification of Diseases (9th revision, clini-
cal modification) discharge diagnosis code of 410.01
through 410.91 for AMI.
Hospitals were considered urban if located in a county
with at least one city having a population .50,000 or two
cities having a combined population .50,000. Treatment
intervals for administration of thrombolytic therapy were
defined according to the National Heart Attack Alert
Program, where “door” indicates the time of patient presen-
tation to the hospital; “data” represents the time of acqui-
sition of the diagnostic ECG; “decision” means the time it
was decided to administer thrombolytic therapy; and “drug”
indicates the time thrombolytic therapy was initiated (4).
Major bleeding included hemorrhagic episodes, other than
intracranial bleeding, resulting in substantial hemodynamic
compromise. Because many hospitals “dropped out” and
“dropped into” the registry over time, “core hospitals” were
identified; they contributed at least six patients during each
six-month interval throughout NRMI 2 and 3 or the
combined NRMI 1, 2 and 3 intervals. Core hospitals were
identified separately for the NRMI 2 and 3 trend analysis
and for the combined NRMI 1, 2, and 3 analyses.
Statistical analysis. For categoric data, the Mantel-
Haenszel chi-square test was used as the measure of trend.
For continuous data, one-way analysis of variance was used
to test the null hypothesis that multiple population mean
values are all equal. To test median values across multiple
groups, p values were computed using the nonparametric
Brown-Mood test. All statistical analyses were performed
using a commercially available statistical package (SAS 6.12
[1996], SAS Institute, Cary, North Carolina). This report is
based on data processed by the statistical center as of
April 25, 2000.
RESULTS
Characteristics of participating hospitals (Table 1). A
total of 1,249 hospitals contributed patients to NRMI 1;
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
ECG 5 electrocardiogram or electrocardiographic
LBBB 5 left bundle branch block
IV 5 intravenous
NRMI 5 National Registry of Myocardial Infarction
PTCA 5 percutaneous transluminal coronary angioplasty
rt-PA 5 recombinant tissue-type plasminogen activator
Table 1. Characteristics of Participating Registry Hospitals
All Hospitals Core Hospitals*
NRMI 1 NRMI 2 and 3
NRMI 2
and 3
NRMI 1,
2 and 3
First Period
(July–Dec. 1990)
Last Period
(Jan.–June 1994)
First Period
(July–Dec. 1994)
Last Period
(Jan.–Dec. 1999)
July 1994–
Dec. 1999
July 1990–
Dec. 1999
No. of hospitals 352 1052 1239 1432 572 58
No. of staffed beds (mean) 322 271 268 250 254 323
Medical school affiliation (%) 48.3 35.0 37.3 35.0 36.0 48.4
Member, Council of Teaching
Hospitals (%)
11.9 8.2 9.9 7.7 6.1 10.2
Urban location (%) 88.4 74.3 79.4 76.2 73.3 86.2
Cardiac catheterization
laboratory (%)
87.1 69.2 72.7 69.0 72.7 89.8
PTCA performed (%) 66.3 43.5 46.0 41.2 44.8 65.9
CABG performed (%) 61.6 27.1 39.5 36.7 38.1 62.4
*Core hospitals were those hospitals contributing at least six patients during each complete six-month period of the registry.
CABG 5 coronary artery bypass graft surgery; NRMI 5 National Registry of Myocardial Infarction; PTCA 5 coronary angioplasty.
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1,843 hospitals to NRMI 2 and 3; and 2,033 hospitals to
NRMI 1, 2 and 3. However, the number of hospitals
participating in the registry at any point in time was variable
and ranged from 352 to 1,460. There were 58 “core”
hospitals for the combined NRMI 1, 2 and 3 experience,
and there were 572 core hospitals for the combined NRMI
2 and 3 experience. The average registry hospital had 250 to
300 beds and was nonteaching and urban and had capabil-
ities for coronary arteriography, but less often percutaneous
transluminal coronary angioplasty (PTCA) or coronary
artery bypass graft surgery (CABG).
Patient characteristics. From 1990 through 1999, 352,742
patients were enrolled in NRMI 1, and 1,161,550 patients
were enrolled in NRMI 2 and 3. The mean age of these
1,514,292 patients increased from 65.3 to 68.0 years from 1990
to 1999, and the proportion of females rose from 35.3% to
39.3% (both p 5 0.0001). Separate analysis of the 1,161,550
patients enrolled in NRMI 2 and 3 between 1994 and 1999
showed similar trends for age and gender, along with an
upward trend for weight (Table 2). In NRMI 2 and 3, payer
status was ascertained and showed a sharp increase in preva-
lence of health maintenance organizations. Also noted was a
reduction in the prevalence of previous angina, but an increase
in previous heart failure, stroke, diabetes, hypertension, hyper-
cholesterolemia or coronary revascularization.
Use of reperfusion therapy. Among the 1,514,292 patients
in the combined NRMI 1, 2 and 3 data set, the proportion
receiving either immediate thrombolytic therapy or primary
PTCA fell from 36.8% in 1990 to 28.1% in 1999 (p 5 0.0001)
(Fig. 1A). During this interval, there was a significant fall in
the use of intravenous (IV) thrombolytic therapy (from 34.3%
to 20.8%, p 5 0.0001), along with a sharp rise in the use of
primary PTCA (from 2.4% to 7.3%, p 5 0.0001).
Occurring simultaneously with the fall in the overall use of
reperfusion therapy was a decrease in patients presenting with
ST segment elevation or left bundle branch block (LBBB)
within 12 h of symptom onset (from 36.4% in 1994 to 27.1%
in 1999, p # 0.001) and an increase in the prevalence of
non–Q wave infarctions (from 45% in 1994 to 63% in 1999,
p 5 0.0001). The proportion of patients having troponin
assays (documented only in NRMI 3) increased from 70.0% in
1998 to 84.3% in 1999 (p 5 0.0001).
Among patients in NRMI 2 and 3 presenting with ST
segment elevation or LBBB within 12 h of symptom onset,
the proportion receiving immediate IV thrombolytic ther-
apy or primary PTCA increased only slightly (from 68.8%
to 70.0%, p 5 0.0014), as the rise in the use of primary
PTCA exceeded the fall in the use of IV thrombolytic
therapy (Fig. 1B). Among patients treated in NRMI 2 and
Table 2. Characteristics of the NRMI 2 and 3 Study Population
Year
p
Value*1994 1995 1996 1997 1998 1999
77,064 205,280 223,395 227,120 215,026 213,665
Age (mean, years) 66.5 66.6 66.8 67.2 67.7 68.0 0.0001
Gender (% female) 37.7 37.7 38.1 38.3 38.8 39.3 0.0001
Race (% white) 86.3 86.5 86.3 85.9 85.4 85.7 0.0001
Weight (mean, kg) 78.0 78.3 78.5 78.6 79.3 79.4 0.0001
Payer status†(%)
Commercial/PPO 22.8 22.8 21.6 20.5 32.7 37.7 0.0001
HMO 7.8 8.3 9.9 12.1 17.1 17.8 0.0001
Medicare 49.1 50.1 50.8 50.9 38.3 33.3 0.0001
Medicaid 3.0 3.0 2.9 2.7 2.6 2.6 0.0001
VA/CHAMPUS 0.9 0.9 0.8 0.7 0.4 0.4 0.0001
Self/other/unknown 16.5 15.0 14.0 13.1 9.0 8.1 0.0001
History (%)
Myocardial infarction 24.5 24.6 24.6 24.6 24.0 24.1 0.0001
Angina 18.6 17.6 16.9 16.4 13.8 12.6 0.0001
Heart failure 11.9 12.3 13.1 13.6 15.2 15.8 0.0001
PTCA 7.0 7.5 8.2 8.8 9.7 10.4 0.0001
CABG 10.6 10.7 11.3 11.9 12.5 12.9 0.0001
Stroke 7.3 7.7 8.0 8.4 9.4 9.7 0.0001
Diabetes 25.1 25.6 26.2 27.0 28.3 28.9 0.0001
Hypertension 48.2 49.8 51.1 52.5 55.1 56.2 0.0001
Current smoking 28.0 28.3 28.3 27.1 26.7 25.9 0.0001
Family member with CAD 29.6 29.7 29.7 29.0 27.8 26.7 0.0001
Hypercholesterolemia 23.1 24.6 25.9 28.6 29.9 31.3 0.0001
*The Mantel-Haenszel test assessed trends by serial time intervals over the duration of the registry. Time interval was six months
in 1994 and 12 months thereafter. One-way analysis of variance was performed to compare group mean values for continuous
fields (age, weight). †Payer categories were mutually exclusive in NRMI 2 and mutually inclusive in NRMI 3. In this table, the
categories for NRMI 3 have been made mutually exclusive by prioritizing in the order of listing above. Thus, a patient with a
Medicare HMO would be categorized in NRMI 3 as “HMO.”
CAD 5 coronary artery disease; CHAMPUS 5 Civilian Health and Medical Program of the Uniformed Services; HMO 5
health maintenance organization; PPO 5 preferred provider organization; VA 5 Veterans Administration; other abbreviations
as in Table 1.
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3 hospitals having the capability for both PTCA and
CABG, the use of IV thrombolytic therapy fell from 59.1%
in 1994 to 47.9% in 1999, whereas the use of primary
PTCA increased from 11.8% to 24.4% (both p 5 0.0001).
Time to treatment. Among the 1,514,292 patients en-
rolled in NRMI 1, 2 and 3, the interval from symptom onset
to hospital arrival fell only marginally between 1990 and
1999 (from a median of 2.2 to 2.0 h, p 5 0.0001).
Door-to-drug time was recorded only for recombinant
tissue-type plasminogen activator (rt-PA) in NRMI 1.
Among the 295,056 patients treated with rt-PA in NRMI
1, 2 and 3, the median interval from hospital arrival to
initiating rt-PA (door-to-drug time) shortened significantly
(Fig. 2A) (from 61.8 to 37.8 min, p 5 0.0001). In NRMI
2 and 3, the door-to-drug time, as well as its component
time intervals, was assessed for recipients of all IV throm-
bolytic agents. Among 266,177 such patients, the median
door-to-drug time fell from 47 min in 1994 to 38 min in
1999, primarily due to shortening of the door-to-data
interval (from 15.0 to 10.8 min) and a reduction in the
data-to-decision interval (from 19.2 to 15.0 min, all p 5
0.0001) (Fig. 2B).
The frequency of consulting another physician before
initiating thrombolytic therapy fell from 57.4% to 49.9%
during NRMI 2 (p 5 0.0001). Among thrombolytic recip-
ients during this same time frame, the prevalence of emer-
gency physicians as prescribers of the thrombolytic therapy
increased from 50.7% to 65.7%, and the prevalence of
cardiologists as the prescribing physician fell from 32.6% to
22.2% (both p 5 0.0001)
Medication use in first 24 h (Fig. 3). During the first 24 h
after presentation, the 1,161,550 patients in NRMI 2 and 3
showed upward trends in the use of aspirin, IV beta-
blockers, oral beta-blockers, angiotensin-converting enzyme
(ACE) inhibitors, antiplatelet therapy other than aspirin (all
p 5 0.0001) and antithrombin therapy other than heparin
(p 5 0.0018). Also noted was less use of calcium channel
blockers, IV lidocaine, IV nitroglycerin and unfractionated
heparin (all p 5 0.0001). Among the 298,486 recipients of
IV thrombolytic therapy in NRMI 2 and 3, similar upward
trends were noted for aspirin (from 88.6% to 93.5%), IV
beta-blockers (from 24.3% to 36.6%), oral beta-blockers
(from 35.5% to 49.6%), either IV or oral beta-blockers
(from 48.4 to 66.9%) and ACE inhibitors (from 7.5% to
18.9%) (all p 5 0.0001).
Noninvasive and invasive procedures. Among the
1,161,550 patients in NRMI 2 and 3, the performance of
echocardiography during the hospital period was unchanged
Figure 1. Use of reperfusion therapy in all patients and in those presenting
with ST segment elevation or LBBB within 12 h of symptom onset. A, A
total of 1,514,292 patients were enrolled in NRMI 1, 2 and 3. B, A total
of 376,753 patients in NRMI 2 and 3 presented with ST segment elevation
or LBBB within 12 h of symptom onset. Either 5 either IV lytic or
primary PTCA; IV lytic 5 intravenous thrombolytic therapy.
Figure 2. Door-to-drug intervals. A, Door-to-drug interval in 295,056
patients treated with rt-PA. Although the time to treatment shortened
significantly, it did not achieve the goal of 30 min. B, Door-to-drug
subintervals in 266,177 patients treated with all IV thrombolytic agents.
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from 1994 through 1999 (from 45.1% to 46.3%, p 5 0.94),
but stress testing decreased (from 11.6% to 8.5%, p 5
0.0001). Among the 1,514, 292 patients in NRMI 1, 2 and
3, performance of coronary arteriography and CABG de-
creased from 1990 through 1999 (61.2% to 50.6% and
13.4% to 9.0%, respectively), whereas PTCA increased
(from 23.5% to 26.1%) (all p 5 0.0001). Among the more
invasively equipped NRMI 1, 2 and 3 core hospitals,
performance of coronary arteriography and PTCA increased
(63.2% to 63.9% and 24.3% to 36.2%, respectively), but
CABG decreased (from 14.0% to 11.8%) (all p 5 0.0001).
Hospital outcome. Among the 1,161,550 patients in
NRMI 1, 2 and 3, the duration of hospital stay declined
sharply (from a median of 8.3 days in 1990 to 4.3 days in
1999, p 5 0.0001) (Fig. 4). The fall in length of hospital
stay among patients receiving primary PTCA or IV throm-
bolytic therapy was similar to that of all patients. During
this same interval, hospital mortality fell (from 11.2% in
1990 to 9.4% in 1999, p 5 0.0001) (Fig. 5). Hospital
mortality also declined among patients receiving primary
PTCA or IV thrombolytic therapy, but in the latter group,
the decline was not quite as sharp as in the overall
population. Among patients in NRMI 2 and 3 in whom the
initial ECG findings were tabulated, similar mortality
trends were noted between 1994 and 1999 for those
presenting with findings of ST segment elevation or LBBB
(n 5 533,452) or for those presenting without such findings
(n 5 628,098) (10.6% to 9.8% and 9.9% to 9.1%, respec-
tively, both p 5 0.0001).
To account for a possible confounding influence of the
shorter duration of hospital stay on mortality, trends for
mortality during each day of hospital stay were examined.
Among all patients, day 1 mortality fell from 3.1% in 1990
to 2.5% in 1999; day 2 mortality from 2.0% to 1.6%; and day
3 mortality from 1.6% to 1.4% (all p 5 0.0001). More
striking trends were noted among females and the elderly.
For example, among the 339,290 female patients .70 years
of age, day 1 mortality fell from 6.1% in 1990 to 4.3% in
1999; day 2 mortality from 4.8% to 2.7%; and day 3
mortality from 3.4% to 2.4% (all p 5 0.0001).
Among the 1,161,550 patients in NRMI 2 and 3, a
reduction was noted for cardiogenic shock (from 5.6% to
4.5%), sustained ventricular tachycardia or fibrillation (from
7.8% to 6.4%), reinfarction (from 3.3% to 1.8%), total
stroke (from 1.5% to 1.1%) and cardiac rupture or electro-
mechanical dissociation (from 0.9% to 0.6%). Major bleed-
ing increased slightly (from 2.6% to 2.7%) (all p 5 0.0001).
Discharge medications (Fig. 6). Among the 805,341 pa-
tients in NRMI 2 and 3 who were discharged alive and not
transferred out of the registry hospitals, upward trends were
noted between 1994 and 1999 for discharge prescription of
aspirin, beta-blockers, ACE inhibitors, antiarrhythmic
agents and diuretic agents. Downward trends were observed
for prescription of nitrates, calcium channel blockers and
Figure 3. Medication (Meds) usage during first 24 h after hospital
admission among 1,161,550 patients in NRMI 2 and 3. Ca blocker 5
calcium channel blocker; TNG 5 nitroglycerin.
Figure 4. Length of hospital stay among 1,514,292 patients in NRMI 1, 2
and 3. The length of stay shortened among all patients and in those
receiving IV thrombolytic therapy or primary PTCA. IV lytic 5 intrave-
nous thrombolytic therapy.
Figure 5. Hospital mortality among 1,514,292 patients in NRMI 1, 2 and
3. Hospital mortality declined among all patients and in those receiving IV
thrombolytic therapy and primary PTCA. IV lytic 5 intravenous throm-
bolytic therapy.
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digoxin (all p 5 0.0001). Usage of lipid-lowering therapy,
recorded only in NRMI 3, increased from 29.2% in 1998 to
36.2% in 1999 (p 5 0.0001).
Core hospitals. Except where noted, all of the temporal
trends reported above for the total population of patients
enrolled in NRMI 1 and 2, or NRMI 2 and 3 separately,
were confirmed in independent analyses of patients enrolled
at the core hospitals for these registries during the respective
time frames (data not shown).
DISCUSSION
The NRMI is the largest data base of AMI in the world,
currently enrolling patients from over one-fourth of all
acute-care hospitals in the U.S. This report shows that,
from 1990 through 1999, practice patterns evolved generally
in accordance with recommendations of recent clinical trials
and published guidelines and resulted in more rapid imple-
mentation of thrombolytic therapy and greater use of
appropriate adjunctive therapy. In parallel with ongoing
national health care reform, there was an increase in health
maintenance organizations as the primary payer for infarct-
related admissions and a sharp reduction in hospital stays.
In accordance with physician preference, there was a steep
increase in the use of primary PTCA and a decrease in the
use of thrombolytic therapy. Finally, hospital mortality
declined, both in patients receiving and in patients not
receiving reperfusion interventions.
Changing patterns for utilization of reperfusion therapy.
Because reperfusion therapy lowers the mortality of AMI, it
should be implemented in every eligible patient (5). Sur-
prisingly, the proportion of patients receiving an early
reperfusion intervention declined from 1990 through 1999
(Fig. 1A). In large part, this may have been due to a
declining eligibility for reperfusion, rather than to an in-
creasing failure to treat eligible patients. There was a fall in
the proportion of patients presenting within 12 h with ST
segment elevation or LBBB, the group known to benefit
from thrombolytic therapy (6). The proportion of such
subjects who were treated with either thrombolytic therapy
or primary angioplasty remained relatively stable (Fig. 1B).
However, as previously noted, over 25% of these patients
did not have an early reperfusion intervention (7). The fact
that the proportion of untreated eligible patients has re-
mained stable since 1994, despite the growing utilization of
primary PTCA, suggests that the latter intervention is being
employed primarily in thrombolytic candidates, rather than
as an “additional” means of reperfusing thrombolytic ineli-
gible patients.
Factors determining time to treatment. Because AMI is a
time-dependent process, the speed of implementation of
thrombolytic therapy is critical in limiting myocardial injury
and mortality (5,8). From 1990 through 1999, the door-to-
drug interval fell significantly in the NRMI population (Fig.
2A), but did not achieve the goal of 30 min, as proposed by
the National Heart Attack Alert Program (4). As previously
reported, the major component of delay is the data-to-
decision time (Fig. 2B), the interval during which “consul-
tation” as to whether thrombolytic therapy should be
administered is often sought between emergency depart-
ment personnel and another physician, such as the patient’s
primary physician, an internist or a cardiologist (9). This
consultative delay may increase both time to treatment and
mortality (9).
To reduce the data-to-decision time, it has been recom-
mended that hospitals empower emergency physicians to
treat patients with typically presenting symptoms of AMI
immediately, without consultation (4). This policy is being
successfully implemented, at least in some NRMI hospitals,
as evidenced by the decline in frequency of consultation
before thrombolysis, the increasing proportion of emergency
physicians as the ones ordering thrombolytic therapy and
the fall in the data-to-decision interval from 1990 through
1999.
Relation of medication usage and procedures to
evidence-based guidelines. Multiple, randomized, con-
trolled clinical trials over the past two decades have inves-
tigated the impact of adjunctive pharmacotherapies and
mechanical interventions on survival after AMI. The
NRMI data show that practitioners have begun to incorpo-
rate many of the findings of these trials into practice.
Medications shown to improve early- and long-term sur-
vival, including aspirin (8,10), beta-blockers (11) and ACE
inhibitors (12), have increased in usage during the first 24 h
of the hospital period (Fig. 3) and at hospital discharge (Fig.
6), whereas the use of agents with potentially deleterious
effects, such as calcium channel blockers (13) and lidocaine
(14) has declined. The use of “other antiplatelet therapy” has
Figure 6. Medications prescribed at hospital discharge. The most notable
upward trends were in medications shown to improve survival, such as
aspirin, beta-blockers and ACE inhibitors. Ca blocker 5 calcium channel
blocker.
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increased in parallel with the increasing prevalence of early
angioplasty. The use of most other agents has remained
stable.
Despite the favorable trends in the utilization of phar-
macologic therapy, there would appear to be potential for
further improvement. Although NRMI did not assess
eligibility for each of the adjunctive therapies, it is likely
that, in recipients of thrombolytic therapy, the most recently
cited rates of utilization were suboptimal for aspirin, beta-
blockers and ACE inhibitors during the first 24 h (93.5%,
66.9% and 18.9%, respectively), especially because the rates
of utilization for these agents was 97.4%, 80.8% and 53.9%,
respectively, in the most recently reported large-scale clin-
ical trial of thrombolytic therapy (15).
Routine coronary arteriography and mechanical revascu-
larization after infarction have not been found to improve
the rates of survival or subsequent AMI in most (6,16–18),
but not all, studies (19). In NRMI, the use of coronary
arteriography declined from 1990 through 1999, but the use
of PTCA increased. The decline in coronary arteriography
was likely an artifact due to the influx into the registry of
hospitals without the capability for invasive procedures.
Indeed, among the stable cohort of NRMI 1, 2 and 3 core
hospitals, the use of both coronary arteriography and PTCA
increased from 1990 through 1999. The relatively high use
of postinfarction coronary arteriography in the U.S., as
reflected by NRMI, represents a singular departure from
otherwise close adherence to the majority of clinical trial
recommendations.
Exercise testing four to six days after infarction, either
before or just after discharge, has been recommended as
appropriate clinical practice (2). However, NRMI data
show that predischarge stress testing is declining and is
currently performed in ,10% of patients. Reasons for the
decline likely include the fact that patients are often dis-
charged before stress testing can be scheduled or safely
undertaken, and because many patients undergo coronary
arteriography and revascularization before discharge.
Changing outcomes for AMI: Hospital stay, mortality
and morbidity. The most impressive trend in the current
report is the dramatic decline in hospital stay (Fig. 4). The
progressive decline in length of stay may be related to the
increasing use of appropriate pharmacologic and mechanical
interventions to limit infarct size and recurrent ischemia.
However, it is likely that the major impetus for early
discharge has been health care reform, specifically the
implementation of “critical pathways” and other quality
control measures to improve efficiency and reduce the cost
of hospital care (20). Although primary PTCA has been
advocated as a means of significantly shortening hospital
stay, as compared with thrombolytic therapy (21), the
differences between length of stay between these two reper-
fusion modalities in the NRMI experience were rather
small.
Hospital mortality declined slightly from 1990 through
1999 in NRMI. The magnitude of mortality decline over
time appeared to be somewhat less among those receiving
IV thrombolytic therapy, a population generally considered
to be at lower risk (22). Among the higher risk, nonthrom-
bolytic recipients, the fall in mortality may have been related
to increasing use of appropriate pharmacologic therapy.
These hospital mortality data should be interpreted with
caution, however. By definition, they do not account for
patients after hospital discharge. Furthermore, they do not
account for patients transferred from the NRMI hospital to
another institution. The trends in hospital mortality may
also have been impacted somewhat by the progressively
shorter lengths of hospital stay. However, individual mor-
tality trend analyses for each of the first three days of
hospital stay showed significant declines from 1990 through
1999. The mortality data may also have been influenced by
changing hospital definitions for AMI over time. With the
adoption of newer serum markers, such as troponin I or T,
a larger proportion of smaller and lower risk infarctions may
have been entered into the registry over time.
Study limitations. The limitations of the NRMI have been
enumerated previously (3), and primarily include the fact
that 1) registry hospitals, though numerous, may not be
representative of all U.S. hospitals; 2) there is no on-site
validation of data collection forms; and 3) there is no
follow-up after hospital discharge. However, a recent study
has shown very close agreement between data collected by
NRMI coordinators and data collected independently by
chart abstractors for the Cooperative Cardiovascular Project
in Medicare-eligible patients at hospitals participating in
both studies (23). A limitation unique to the present report
is the potential for the trend data to be distorted by the
changing hospital composition of the registry. To address
this concern, data were examined from core hospitals that
consistently contributed to the registry over time. In almost
all instances, there was close agreement between the overall
registry data and data of the core hospitals. Another
potential limitation is the fact that, although medication
usage is tracked, NRMI does not attempt to assess clinical
eligibility for each medication. Thus, failure to use certain
medications may reflect contraindications to their use.
However, assuming the characteristics of the population
does not change substantially over time, the trend analyses
still properly reflect the change in frequency of usage of the
medications.
Conclusions. These data from the NRMI during the
period 1990–1999 show that practitioners are initiating
thrombolytic therapy faster, using primary PTCA and
proven life-saving adjunctive pharmacotherapy more com-
monly and discharging patients sooner. There appears to be
a declining hospital mortality for AMI. It is likely that many
of these favorable trends resulted directly from participation
in this registry, which provided participating hospitals with
quarterly summaries of their individual hospital data, along
with that of hospitals of like size and invasive capability.
Despite these favorable trends, it is evident that more
work remains to be done. Over 25% of patients presenting
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within the first 12 h of symptom onset with ST segment
elevation or LBBB fail to receive a reperfusion intervention;
door-to-drug time remains suboptimal, especially the data-
to-decision subinterval; and there is the potential to further
expand the use of potentially beneficial pharmacotherapy
such as aspirin, beta-blockers and ACE inhibitors. Accord-
ingly, the next phase of the registry (NRMI 4) will place
increased emphasis on the identification and treatment of
patients eligible for reperfusion, while continuing to em-
phasize rapid delivery of reperfusion interventions and
appropriate use of adjunctive pharmacotherapy.
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